{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "XRAY",
  "name": "DENTSPLY SIRONA Inc.",
  "url": "https://frontierpicks.com/dossiers/XRAY/",
  "json_url": "https://frontierpicks.com/dossiers/XRAY.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Stock faded from $13.78 pre-print to $11.59 on 2026-08-14 — the narrative leg came and went, and the $11–12 shelf is what remains.",
  "invalidation_trigger": "A weekly close below $11 breaks the low-teens shelf defended since spring and confirms the summer advance was a rally inside the downtrend; secondary: the ~2026-11-04 (est.) Q3 print showing a constant-currency decline worse than Q2's -6.3% or a cut to the $1.40–1.50 FY adjusted EPS guide.",
  "catalyst_date": "2026-09-01",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics",
    "semi-foundry-equipment",
    "cyclical-industrials"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Dividend eliminated with FY2025 results (announced 2026-02-27); ~$128M/yr redirected to debt paydown and buybacks — no longer a yield name.",
    "Q2 2026 adjusted EPS of $0.52 includes $0.17 from a $44M tariff refund; management excluded tariff effects from the FY2026 EPS guide.",
    "Net debt/EBITDA was 3.2x at Q2 2026, unchanged from Q1 2026, while share repurchases resumed.",
    "Reporting cadence: Q1 2026 on 2026-05-05, Q2 2026 on 2026-08-06; Q3 falls outside any 30-day window from mid-August.",
    "Wellspect Healthcare (continence care) is a non-dental segment inside a dental-branded company and moves on a different end-market cycle."
  ],
  "body_markdown": "## Current Thesis\nThe Q2 print flagged in the prior note as the binary landed on 2026-08-06, and the market faded it. Headline numbers cleared the bar — net sales $898M against a $889.81M consensus, adjusted EPS $0.52 against $0.35 — but $44M of tariff refunds contributed $0.17 of that EPS, sales fell 4.1% reported and 6.3% in constant currency, and management told the call that Q3 earnings would sit below Q2 once the refund is excluded. Press coverage put the 2026-08-06 session at a 4.32% decline to $13.19 from a $13.78 prior close (Investing.com, 2026-08-06); by 2026-08-14 the last close was $11.59, 21.0% under the $14.68 52-week high with RSI(14) at 38.0. The FY2026 frame is unchanged — $3.5–3.6B sales and $1.40–1.50 adjusted EPS reaffirmed — and the self-help programme is still running. What changed is that the event the summer advance was priced into has come and gone, and the re-rating leg reversed on the result. The narrative is **dead** — the narrative leg resolved at the 2026-08-06 print and the tape gave the move back within six sessions.\n\n## Bull Case\n- **Second consecutive top-line beat.** Q2 net sales $898M vs $889.81M consensus (2026-08-06), following Q1's $880M print (2026-05-05). Revenue has stopped missing even while it shrinks.\n- **Cash generation inflected.** Q2 operating cash flow $99M vs $48M in Q2 2025 (2026-08-06 release), against Q1 2026 free cash flow of negative $12M. The cash line moved before the revenue line.\n- **Sequential margin repair.** Adjusted EBITDA margin 21.3% in Q2 vs 14.7% in Q1 2026; adjusted operating margin 15.8% in Q2 vs negative 3.1% in Q1. GAAP diluted EPS $0.18, back in the black.\n- **Buyback restarted.** 1.3 million shares repurchased in Q2 — the first repurchase since Q3 2024 per the 2026-08-06 call — funded from tariff refund proceeds, at an average price management described as below $10.\n- **Guide reaffirmed, not trimmed.** FY2026 sales $3.500–3.600B (vs $3.582B est.) and adjusted EPS $1.40–1.50 (vs $1.42 est.), confirmed 2026-08-06.\n- **Wellspect Healthcare +7.1% YoY in Q2** — the non-dental franchise is the one segment compounding, and it is not exposed to the dental dealer cycle.\n- **Two-way sell-side revisions post-print:** Baird to $15 from $14 and BMO Capital to $13 from $12; Piper Sandler maintained Neutral and raised to $14 on 2026-07-29.\n\n## Bear Case\n- **The beat was refund-assisted.** A $44M tariff refund added $0.17 per share inside the $0.52 adjusted figure; on the 2026-08-06 call management called it \"totally unrelated to the operations of the business\" and excluded tariff effects from the FY EPS guide.\n- **Organic contraction deepened.** Constant-currency sales fell 6.3% in Q2 after Q1's roughly flat +0.1%. The direction of the underlying business worsened quarter over quarter.\n- **Orthodontic and Implant Solutions fell 13.2% YoY in Q2** — the highest-multiple growth franchise is shrinking fastest; Connected Technology Solutions and Essential Dental Solutions also declined.\n- **YoY margin still down.** Adjusted operating margin 15.8% vs 18.2% a year earlier, with the refund sitting inside the quarter.\n- **Q3 pre-guided lower.** Management flagged seasonal sequential revenue decline and earnings below Q2 ex-refund, with \"more of the improvement weighted towards the fourth quarter\" (2026-08-06 call). A back-loaded plan concentrates the risk in one print.\n- **Leverage unmoved.** Net debt/EBITDA 3.2x at Q2, unchanged from Q1 2026, while cash is being routed to repurchases.\n- **The tape rejected the result.** A revenue and EPS beat produced a down session and an eight-day drift to $11.59 — below the $13, $14 and $15 targets published around the print.\n\n## Setup & Price Structure\nReference close 2026-08-14: $11.59; 52-week high $14.68 (-21.0%); RSI(14) 38.0; three-month return +15.1%. The shape is a summer advance into a known event, a gap rejection at the print, and no reclaim since. Price sits at the top of the $11–12 shelf that has contained the downside since spring, inside the broader $11–15 band the stock has traded all year and far below the $40-plus highs of 2021–22. There is no moving-average reclaim to point at and RSI at 38 is weak rather than washed out, so the base is unproven at this level.\n\nPositioning and crowding observables, stated as observables: no earnings date falls inside the next 30 days — the next print is estimated early November — so the event that concentrated attention in July and early August is gone. Sell-side dispersion is wide and two-way: post-print raises from Baird ($15) and BMO ($13) against reported target cuts from Barclays, Mizuho, Citi and Evercore ISI, with a Hold consensus straddling spot. The issuer itself was a buyer in Q2 (1.3 million shares) rather than a seller of stock into strength. No insider Form 4 activity surfaced in the 30-day window reviewed here. Retail-sentiment clustering around the name is not visible in the coverage feed; what coverage exists is earnings-recap, not thematic.\n\n## Catalyst Calendar (next 30 days)\n- **2026-09-01 — Medline Sinclair begins distributing the Connected Technology Solutions portfolio across Canada** (announced 2026-07-28). Low-impact and non-binary: the first measurable effect would appear in Q4 CTS revenue, not in any September datapoint.\n- **~2026-11-04 (est.) — Q3 2026 earnings.** Outside the window, named because it is the next binary. Q2 was reported 2026-08-06, Q1 on 2026-05-05. Management has already pre-guided Q3 below Q2 excluding the $0.17 refund, so the bar is the FY guide's back-half arithmetic, not the quarter itself.\n- No confirmed conference appearance, regulatory decision or scheduled corporate event inside the 30-day window.\n\n## What Would Change Our Mind\nThe structure that matters is the $11–12 shelf defended since spring; the post-print fade has walked price to the top of it, so the shelf gets tested rather than admired. A weekly close below $11 would say the low-teens base failed and that the mid-May-to-August advance was a rally inside a multi-year downtrend. Secondary conditions that would confirm the same read without a price break: the Q3 print (~2026-11-04 est.) showing a constant-currency decline worse than Q2's -6.3%, or any trim to the $1.40–1.50 adjusted EPS guide reaffirmed on 2026-08-06.\n\nOn the other side, the case for re-engagement would need price to close a week back above $13.78 — the 2026-08-05 pre-print close, which is what the gap rejection took away — paired with a Q3 organic sales line that stops contracting and an operating margin that holds above the 15.8% Q2 level without a one-time refund inside it. Absent both, this is a cheap multiple with a shrinking top line and a plan whose proof point is a quarter away; standing aside until a base forms is the defensible read.\n\n## Correlation Notes\n- **Dental capex and consumables cycle:** results read across to Envista (NVST), Align Technology (ALGN), Henry Schein (HSIC) and Patterson. Q2 weakness was company-attributed to dental end markets, with Ortho and Implant Solutions -13.2%.\n- **Wellspect Healthcare decouples part of the base.** The continence-care unit grew 7.1% in Q2 and does not share the dental dealer-inventory cycle.\n- **Tariff policy is a direct P&L input, not a macro backdrop.** A $44M refund landed in Q2 2026 and management excluded tariff effects from FY guidance, so further rulings can move reported EPS with no change in demand.\n- **FX flatters the reported line.** Q2 was -4.1% reported vs -6.3% constant currency; a dollar reversal widens the reported decline.\n- **Rate sensitivity via the balance sheet:** net debt/EBITDA of 3.2x makes refinancing costs a live variable alongside the deleveraging plan announced 2026-02-27.",
  "first_seen": "2026-07-16",
  "last_analyzed": "2026-08-15T09:31:21+00:00",
  "last_synthesized": "2026-08-15",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}